Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL



Status:Recruiting
Conditions:Blood Cancer, Infectious Disease, Lymphoma
Therapuetic Areas:Immunology / Infectious Diseases, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:February 2016
End Date:December 2020

Use our guide to learn which trials are right for you!

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics
and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients
diagnosed with certain lymphomas and leukemias, including cutaneous T-cell lymphoma (CTCL)
[mycosis fungoides (MF) subtype], chronic lymphocytic leukemia (CLL), diffuse large B-cell
lymphoma (DLBCL) [activated B-cell (ABC) subtype], and adult T-cell leukemia/lymphoma (ATLL).
Cobomarsen is an inhibitor of a molecule called miR-155 that is found at high levels in these
types of cancers and may be important in promoting the growth and survival of the cancer
cells. Participants in the clinical trial will receive weekly doses of cobomarsen
administered by injection under the skin or into a vein, or by injection directly into
cancerous lesions in the skin (for CTCL only). Blood samples will be collected to measure how
cobomarsen is processed by the body, and other measurements will be performed to study how
normal and cancerous cells of the immune system respond when exposed to cobomarsen.

Study Design:

- Part A: Cohorts of 3-6 patients diagnosed with MF will receive up to five intratumoral
injections of cobomarsen over a period of up to 15 days with follow-up for an additional
20 days, beginning with the maximum deliverable intratumoral dose. Doses may be
decreased in subsequent cohorts to determine the minimum pharmacodynamically active
dose.

- Parts B-F: Patients in these parts of the study will be diagnosed with MF (Parts B and
C), CLL (Part D), DLBCL (Part E), or ATLL (Part F). All patients will receive
subcutaneous or intravenous cobomarsen (or a combination of systemic and intratumoral
administration for MF patients only) on Days 1, 3 and 5, and will continue dosing on a
weekly schedule until the patient becomes intolerant, develops clinically significant
side effects, progresses, or the trial is terminated. Doses administered will not exceed
a dose level predicted to be safe based on all prior treatment experience with the drug.
Patients in Part B may continue on a stable background therapy for their disease during
their treatment with cobomarsen, while patients in Parts C-F will be treated with
cobomarsen alone.

Inclusion Criteria:

- Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III
(excluding visceral or nodal involvement), and must be refractory to or intolerant of
established therapies for their condition

- Part D only: Patients diagnosed with CLL who are intolerant to, or have disease that
is relapsed/refractory after, at least two prior therapies

- Part E only: Patients with biopsy-proven DLBCL who are intolerant to, or have disease
that is relapsed/refractory after, at least two prior therapies, including any
anti-CD20 monoclonal antibody and chemotherapy with curative intent

- Part F only: Patients with documented HTLV-1 infection and histologically or
cytologically proven ATLL of any stage, and who are intolerant to, or have disease
that is relapsed/refractory after, at least one prior therapy

- Females must not be pregnant or lactating. Women of child-bearing potential must use a
highly effective method of contraception throughout their study participation and for
at least 6 months following the last dose of study drug.

- Males must be surgically sterile, abstinent, or if engaged in sexual relations with a
female of child-bearing potential, must be willing to use a highly effective method of
contraception throughout their study participation and for at least 6 months after the
last dose of study drug.

Exclusion Criteria:

- Evidence of renal or liver dysfunction at screening

- Clinically significant anemia, neutropenia or thrombocytopenia at screening

- History of bleeding diathesis or coagulopathy

- Clinically significant cardiovascular disease, history of myocardial infarction within
the last 6 months, or evidence of QTc interval prolongation at screening

- Serologically positive for HIV; serologically positive for Hepatitis B or Hepatitis C
with evidence of liver dysfunction or documented liver cirrhosis

- Prior malignancies within the past 3 years (with allowance for adequately treated in
situ carcinoma of the cervix uteri, and basal cell or localized squamous cell
carcinoma of the skin treated with curative intent)

- Use of an investigational small molecule drug during the 30 days prior to screening or
use of an investigational oligonucleotide or biologic drug during the prior 90 days
We found this trial at
19
sites
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: William Wierda, MD
Phone: 713-794-1447
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Robin Joyce, MD
Phone: 617-667-9920
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
13001 E 17th Pl
Aurora, Colorado 80045
(303) 724-5000
Principal Investigator: Theresa R. Pacheco, MD
Phone: 720-848-9384
University of Colorado Anschutz Medical Campus Located in the Denver metro area near the Rocky...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Murali Janakiram, MD
Phone: 718-920-4826
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Joan Guitart, MD
Phone: 312-503-5900
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Basem William, MD
Phone: 614-366-3872
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Christiane Querfeld, MD
Phone: 626-256-4673
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Fairfax, Virginia 22003
Principal Investigator: Jennifer DeSimone, MD
Phone: 703-208-6606
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
La Jolla, California 92093
Principal Investigator: Thomas Kipps, MD, PhD
Phone: 858-822-0743
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Herbert Eradat, MD
Phone: 310-794-6500
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1475 NW 12th Ave
Miami, Florida 33136
(305) 243-1000
Principal Investigator: Juan Carlos Ramos, MD
Phone: 305-243-7359
University of Miami, Sylvester Comprehensive Cancer Center Sylvester Comprehensive Cancer Center integrates all cancer-related activities...
?
mi
from
Miami, FL
Click here to add this to my saved trials
New Haven, Connecticut 06520
Principal Investigator: Francine Foss, MD
Phone: 203-737-8884
?
mi
from
New Haven, CT
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Alison Moskowitz, MD
Phone: 212-639-4839
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: Adrienne A. Phillips, MD
Phone: 212-746-1362
?
mi
from
New York, NY
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Principal Investigator: Matthew A. Lunning, DO
Phone: 402-559-9053
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orange, California 92868
Principal Investigator: Lauren Pinter-Brown, MD
Phone: 877-827-8839
?
mi
from
Orange, CA
Click here to add this to my saved trials
111 S 11th St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: Pierluigi Porcu, MD
Phone: 215-955-0030
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Salt Lake City, Utah 84112
Principal Investigator: Ahmad Halwani, MD
Phone: 801-581-4477
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
300 Pasteur Dr
Stanford, California 94305
(650) 723-4000
Principal Investigator: Youn Kim, MD
Phone: 650-421-6370
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
?
mi
from
Stanford, CA
Click here to add this to my saved trials